Development of apixaban: A novel anticoagulant for prevention of stroke in patients with atrial fibrillation

Annals of the New York Academy of Sciences

Volumn 1329, Issue 1, 2014, Pages 93-106

  Hanna, Michael S ^a   Mohan, Puneet ^b   Knabb, Robert ^a   Gupta, Elora ^c   Frost, Charles ^a   Lawrence, John H ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b Pharmaceutical Product Development   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Anticoagulation; Apixaban; Atrial fibrillation; Factor Xa inhibition; Stroke prevention

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ANTICOAGULATION; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL PHARMACOLOGY; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HUMAN; META ANALYSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; ANIMAL; ATRIAL FIBRILLATION; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; STROKE; TRENDS;

ANIMALS; ANTICOAGULANTS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; FACTOR XA INHIBITORS; HUMANS; PYRAZOLES; PYRIDONES; STROKE;

EID: 84910631118     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12567     Document Type: Article

References (41)

1. Hart, R.G., L.A. Pearce & M.I. Aguilar. 2007. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 146: 857-867.
2. Baker, W.L., D.A. Cios, S.D. Sander, et al. 2009. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J. Manag. Care. Pharm. 15: 244-252.
3. Singer, D.E., G.W. Albers & J.E. Dalen; American College of Chest Physicians. 2008. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl.): 546S-592S.
4. Harker, L.A., S.R. Hanson & A.B. Kelly. 1995. Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists. Thromb. Haemost. 74: 464-472.
5. Morishima, Y., K. Tanabe, Y. Terada, et al. 1997. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants. Thromb. Haemost. 78: 1366-1371.
6. Sato, K., T. Kawasaki, Y. Taniuchi, et al. 1997. YM-60828, a novel factor Xa inhibitor: separation of its antithrombotic effects from its prolongation of bleeding time. Eur. J. Pharmacol. 339: 141-146.
7. Wong, P.C., E.J. Crain, C.A. Watson, et al. 2002. Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits. J. Pharmacol. Exp. Ther. 303: 993-1000.
8. Wong, P.C., E.J. Crain, C.A. Watson, et al. 2009. Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits. J. Thromb. Haemost. 7: 1313-1320.
9. Pinto, D.J.P., P.C. Wong, R.M. Knabb, et al. 2012. "Case history: eliquis (apixaban), a potent and selective inhibitor of coagulation factor Xa for the prevention and treatment of thrombotic diseases." In Annual Reports in Medicinal Chemistry. Vol. 47. M.C. Desai, Ed.: 123-141. Burlington: Academic Press.
10. Pinto, D.J., J.M. Smallheer, D.L. Cheney, et al. 2010. Factor Xa inhibitors: next-generation antithrombotic agents. J. Med. Chem. 53: 6243-6274.
11. Quan, M.L., P.Y. Lam, Q. Han, et al. 2005. Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor. J. Med. Chem. 48: 1729-1744.
12. Wong, P.C., E.J. Crain, B. Xin, et al. 2008. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J. Thromb. Haemost. 6: 820-829.
13. Schumacher, W.A., J.S. Bostwick, A.B. Stewart, et al. 2010. Effect of the direct factor Xa inhibitor apixaban in rat models of thrombosis and hemostasis. J. Cardiovasc. Pharmacol. 55: 609-616.
14. He, K., J.M. Luettgen, D. Zhang, et al. 2011. Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. Eur. J. Drug. Metab. Pharmacokinet. 36: 129-139.
15. Lassen, M.R., B.L. Davidson, A. Gallus, et al. 2007. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J. Thromb. Haemost. 5: 2368-2375.
16. Leil, T.A., Y. Feng, L. Zhang, et al. 2010. Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose. Clin. Pharmacol. Ther. 88: 375-382.
17. Lassen, M.R., G.E. Raskob, A. Gallus, et al. 2009. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N. Engl J. Med. 361: 594-604.
18. Lassen, M.R., G.E. Raskob, A. Gallus, et al.; ADVANCE-2 Investigators. 2010. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 375: 807-815.
19. Lassen, M.R., G.E. Raskob, A. Gallus, et al. 2010. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N. Engl. J. Med. 363: 2487-2498.
20. Buller, H., D. Deitchman, M. Prins, et al.; Botticelli Investigators, Writing Committee. 2008. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep-vein thrombosis. The Botticelli DVT dose-ranging study. J. Thromb. Haemost. 6: 1313-1318.
21. Go, A.S., E.M. Hylek, K.A. Phillips, et al. 2001. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. J. Am. Med. Assoc. 285: 2370-2375.
22. Lin, H.J., P.A. Wolf, M. Kelly-Hayes, et al. 1996. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 27: 1760-1764.
23. Heeringa, J., D. Kuip, A. Hofman, et al. 2006. Prevalence, incidence, and lifetime risk of atrial fibrillation: the Rotterdam study. Eur. Heart. J. 27: 949-953.
24. Rosamond, W., K. Flegal, K. Furie, et al. 2008. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117: e25-e146.
25. Wolf, P.A., R.D. Abbott & W.B. Kannel. 1991. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22: 983-988.
26. Marini, C., F. de Santis, S. Sacco, et al. 2005. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 36: 1115-1119.
27. Camm, A.J., G.H.Y. Lip, R. De Caterina, et al. 2012. Focused update of the ESC guidelines for the management of AF. Eur. Heart. J. 33: 2719-2747.
28. Glader, E.L., M. Sjölander & M. Eriksson. 2010. Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke 41: 397-401.
29. Granger, C.B., J.H. Alexander, J.J.V. McMurray, et al.; for the ARISTOTLE committees and investigators. 2011. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365: 981-992.
30. Hart, R.G., O. Benavente, R. McBride, et al. 1999. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann. Intern. Med. 131: 492-501.
31. Connolly S.J., J. Eikelboom, C. Joyner, et al. 2011. Apixaban in patients with atrial fibrillation. N. Engl. J. Med. 364: 806-817.
32. McMurray, J.J.V., S.J. Connolly, R. Hart, et al. 2012. Effect of apixaban on all-cause mortality in atrial fibrillation: an imputed placebo analysis. Eur. Heart. J. 33(1 Suppl.): 519.
33. Pengo, V., C. Pegoraro, U. Cucchini, et al. 2006. Worldwide management of oral anticoagulant therapy: the ISAM study. J. Thromb. Thrombolysis. 21: 73-77.
34. van Walraven, C., A. Jennings, N. Oake, et al. 2006. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 129: 1155-1166.
35. McBride, D., B. Bruggenjurgen, S. Roll, et al. 2007. Anticoagulation treatment for the reduction of stroke in atrial fibrillation: a cohort study to examine the gap between guidelines and routine medical practice. J. Thromb. Thrombolysis. 24: 65-72.
36. Rose, A.J., E.M. Hylek, A. Ozonoff, et al. 2011. Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the veterans affairs study to improve anticoagulation (VARIA). Circ. Cardiovasc. Qual. Outcomes. 4: 22-29.
37. Wallentin, L., R.D. Lopes, M. Hanna, et al.; ARISTOTLE Investigators. 2013. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation 127: 2166-2176.
38. Connolly, S.J., M.D. Ezekowitz, S. Yusuf, et al.; RE-LY Steering Committee and Investigators. 2009. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361: 1139-1151.
39. Patel, M.R., K.W. Mahaffey, J. Garg, et al.; ROCKET AF Investigators. 2011. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365: 883-891.
40. Eikelboom, J.W., L. Wallentin, S.J. Connolly, et al. 2011. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 123: 2363-2372.
41. Nagarakanti, R., M.D. Ezekowitz, K. Parcham-Azad, et al. 2008. Abstract 4629: long-term open label extension of the prevention of embolic and thrombotic events on dabigatran in atrial fibrillation (PETRO- Ex study). Circulation 118: S_922.